Abstract
The lack of harmonization of legislation, guidance and procedures for conducting clinical trials in Europe is generally considered unsatisfactory, despite the implementation of the Clinical Trials Directive in 2004. This article outlines the measures being taken by the Clinical Trials Facilitation Group of the Heads of Medicines Agencies and the Ad Hoc Clinical Trials Group of the European Commission to improve authorization, amendment and safety monitoring for clinical trials. It also comments, from a UK perspective, on the current status of the Commission’s consultation and impact assessment on potential changes to the Clinical Trials Directive, and anticipates the likely changes in the next 5 years.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
